ALS Therapy Development Institute, USA
"Assessment of ALS disease progression from accelerometer and voice recordings using machine learning with application to the evaluation of real-world drug efficacy"
Fernando G. Vieira, M.D. is the Chief Scientific Officer at the ALS Therapy Development Institute. He has worked in ALS research for more than 19 years. He led the preclinical research identifying CD40 ligand as a therapeutic target for ALS and was a member of the team that invented AT1501 – an ALS clinical candidate. His recent basic research focuses have been implications of SOD1 aggregation in vivo and mechanisms of C9ORF72 dipeptide toxicity. His translational research has focused on the application of digital outcome measures and machine learning for the assessment of ALS symptom progression.